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Abstract 
Serum magnesium is an essential intracellular cation involved in processes that regulate cardiovascular 
function and has been linked to the risk of several cardiovascular disease outcomes. We aimed to 
investigate the association of serum magnesium concentrations with risk of incident heart failure (HF). We 
studied 2,181 middle-aged men without prevalent HF (aged 42-61 years) enrolled in the Finnish Kuopio 
Ischemic Heart Disease prospective cohort study with serum magnesium measurements made at baseline. 
Hazard ratios (95% confidence intervals [CI]) for HF were assessed. During a median follow-up of 24.8 
years, 278 HF events occurred. Baseline serum magnesium was weakly and inversely associated with 
several clinical markers and was continuously associated with risk of HF. The age-adjusted HR (95% CIs) 
for HF per 1 standard deviation (SD) higher serum magnesium levels was 0.86 (0.76-0.97). The HR (95% 
CIs) was 0.87 (0.76-0.98) after controlling for measures of adiposity, socio-economic variables, medical 
history, blood pressure, renal function, alcohol consumption, and lipids. These findings remained 
consistent in analyses accounting for incident coronary heart disease. The results were comparable across 
several clinically relevant subgroups and analyses with atrial fibrillation as a competing risk yielded 
similar results. Serum magnesium was continuously, inversely and independently associated with future 
risk of HF. Further research is needed to assess any potential relevance of serum magnesium in HF 
prevention. 
 
Keywords: serum magnesium; heart failure; risk factor 
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Introduction 
Magnesium is a key intracellular cation, involved in several homeostatic processes including enzymatic 
reactions, nucleic acid synthesis, and cell replication. It is also involved in processes that regulate 
cardiovascular function, including regulation of muscular function, endothelial cell function, myocardial 
excitability, and activation of sodium potassium ATPase.(1-4) Serum magnesium has been linked to 
chronic kidney disease (5, 6) and several cardiovascular disease (CVD) outcomes. Inverse associations 
have been demonstrated for atrial fibrillation,(7) sudden cardiac death,(8) coronary heart disease 
(CHD),(9, 10) stroke,(11) fatal CVD,(12) and all-cause mortality events.(12) Data on the etiological 
nature of the prospective association between serum magnesium levels and risk of heart failure (HF) is 
sparse. In the only population-based prospective study conducted till date, Lutsey and colleagues 
demonstrated a linear inverse and independent association between serum magnesium levels and risk of 
HF.(13) Magnesium may be related to HF risk through multiple pathways. Interestingly, several direct 
myocardial effects of magnesium have been demonstrated.(14) Thus, it is possible that magnesium may 
confer cardio-protective effects. Given that HF is associated with high morbidity and mortality2 and 
imposes a significant economic burden on health systems, it is therefore necessary to further evaluate 
putative risk factors which may have predictive or causal relevance to the risk of HF and which could help 
tailor preventive and therapeutic interventions. In this context, our objective was to assess the shape, 
nature, and magnitude of the prospective association of serum magnesium with risk of HF and the 
consistency of the association in important clinical subgroups using a population-based cohort of 2,181 
relatively healthy men from eastern Finland who were free of HF at baseline.  
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Methods 
Study population 
The study used data from the Kuopio Ischaemic Heart Disease (KIHD) risk factor study, a population-
based prospective cohort study which was set up to investigate risk factors for CV and other chronic 
diseases in eastern Finland.(15) A baseline study was conducted between March 1984 and December 
1989, which included a representative sample of 3,433 men aged 42-61 years living in the city of Kuopio 
and its neighbouring rural communities. Of the 3,433 randomly selected and eligible men, 2,682 (78%) 
volunteered to participate; 186 did not respond to the invitation and 367 declined to give informed 
consent. Men with a prevalent history of HF were excluded. The final cohort for the present analysis 
included 2,181 men with non-missing information on serum magnesium and several risk markers for HF. 
The KIHD study complies with the Declaration of Helsinki and was approved by the ethical committee of 
the University of Eastern Finland and each study participant gave written informed consent. 
 
Ascertainment of outcomes 
All HF events that occurred from the study entry to 2013 were included and there were no losses to 
follow-up. In the KIHD study, participants are under annual continuous surveillance for the development 
of new cardiovascular outcome events, including new incident HF cases.(16) Information on 
cardiovascular outcomes were obtained from the National Hospital Discharge Register data by computer 
linkage and a comprehensive review of hospital records and discharge diagnoses, inpatient physician 
claims data, study ECGs, and medico-legal reports. The events were coded according to ICD-10 codes 
(I50.0-I50.9, I11, I42.0-I42.9). The diagnosis of HF was based on symptoms, physical examination by a 
doctor, laboratory investigations including the determination of natriuretic peptides, chest radiography, 
echocardiography as well as electrocardiographic findings.(17) Documents were cross-checked in detail 
by two physicians. The Independent Events Committee, masked to clinical data, performed classification 
of outcomes. 
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Measurement of risk factors 
Collection of blood specimens and the measurement of serum lipids, lipoproteins and glucose have been 
described in detail previously.(18) In addition to fasting, participants were instructed to abstain from 
drinking alcohol for at least 3 days and from smoking for at least 12 h prior to assessment. The serum 
samples were stored frozen at -80 °C for 0.2-2.5 years. Fasting plasma glucose (FPG) was measured by 
the glucose dehydrogenase method (Merck, Darmstadt, Germany). Serum magnesium was measured using 
atomic absorption spectrometry (Perkin Elmer Zeeman 5000, Perkin Elmer, Norwalk, CT, USA) which 
involved the use of acetylene-air (1:4) flame technique. Serum magnesium was diluted in a ratio of 1:50 
with distilled water. The wavelength was 185.2 nm for magnesium. The between-run Coefficient of 
Variation% for the method was 2.4 (37 assays).(19) Measurements of serum potassium and zinc have been 
described previously.(18, 20) Data on age, smoking, alcohol consumption, history of CVD, presence of 
hypertension, and use of medication was obtained using self-administered questionnaire. Re-interviews 
were conducted again by a physician to collect information on medical history.(18) Resting blood pressure 
was measured by a nurse on the first examination day with a random zero sphygmomanometer and the 
mean of all 6 measurements (3 supine, 1 standing, 2 sitting) was used as the final mean systolic and 
diastolic blood pressure. Body mass index (BMI) was computed as the ratio of weight in kilograms to the 
square of height in metres. Physical activity was assessed using the validated KIHD 12-month leisure-time 
physical activity questionnaire.(21, 22) 
 
Statistical analyses 
Values of skewed variables were naturally logarithmically transformed to achieve approximately normal 
distributions. Descriptive data were presented in the form of mean (SD) or median (interquartile range) for 
continuous variables and percentages for categorical variables. Cross-sectional correlations of serum 
magnesium levels with various risk markers were determined using age-adjusted linear regression models. 
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Time-to-event analyses were conducted using Cox proportional hazard models. The proportional hazards 
assumptions were confirmed using Schoenfeld residuals as previously described.(23)  To characterize the 
shape of the association, hazard ratios (HRs) were calculated within quartiles of serum magnesium levels 
and plotted against mean serum magnesium levels within each quartile. Floating variances were used to 
calculate 95% confidence intervals for the log hazard ratio in each group, including the reference group, to 
allow for comparisons across the groups irrespective of the arbitrarily chosen reference category (bottom 
quartile).(24) Multivariate-adjusted fractional polynomial models were also fitted to further characterize 
the shape of the association. As the association showed a continuous shape and given the sparse number of 
participants in the upper and lower quartiles of the distribution curve of serum magnesium levels (Figure 
1), HRs were calculated per 1 standard deviation (SD) higher serum magnesium concentrations. The SD of 
serum magnesium concentration was 0.16 mg/dl. Hazard ratios were progressively adjusted for age, BMI, 
systolic blood pressure (SBP), prevalent CHD, smoking status, history of diabetes mellitus, use of 
medications (antihypertensive agents and lipid-lowering drugs), alcohol consumption, triglycerides, total 
cholesterol, high-density lipoprotein cholesterol (HDL-C), estimated glomerular filtration rate (eGFR), as 
calculated using the Chronic Kidney Disease Epidemiology Collaboration formula,(25) socio-economic 
status, physical activity, serum  potassium and serum zinc . Further adjustment included incident coronary 
events as a time-varying covariate. Given that AF was higher than HF incidence in the KIHD cohort, we 
also performed additional analyses using the competing-risks extension of the Cox proportional hazards 
models, as proposed by Fine and Gray,(26) to estimate the baseline cumulative subhazard of HF 
considering AF as a competing outcome to HF. We performed subgroup analyses using interaction tests to 
assess statistical evidence of any differences in hazards across categories of pre-specified individual level 
characteristics. To avoid potential bias due to participants at high risk of HF or with underlying HF at 
baseline, we carried out sensitivity analyses that excluded the first 5 years of follow-up.  
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To assess whether adding information on serum magnesium measurements to established HF risk factors 
is associated with improvement in prediction of HF risk, we calculated measures of discrimination for 
censored time-to-event data (Harrell’s C-index (27)) and reclassification (the continuous net-
reclassification-improvement [NRI], a category-free version of the NRI).(28) All statistical analyses were 
conducted using Stata version 14 (Stata Corp, College Station, Texas). 
 
Results 
Baseline characteristics and correlates of serum magnesium levels 
The mean (SD) serum magnesium levels at baseline was 1.98 (0.16) mg/dl. Figure 1 shows a histogram 
representing the frequency distribution of magnesium concentrations in the study sample. Table 1 
summarizes baseline characteristics of the study population (n=2,198).The mean (SD) of study 
participants was 53 (5) years. Serum magnesium levels were weakly and inversely correlated with 
physical measures (BMI and blood pressure) and with several lipid, metabolic, and renal markers. Weak 
positive correlations were observed for age, total cholesterol, creatinine, and zinc. Baseline serum 
magnesium levels were lower in people with diabetes compared with people without diabetes, people with 
a history of hypertension compared with people without a history of hypertension, and in current smokers 
compared with non-smokers. 
 
Serum magnesium and risk of heart failure 
During a median (interquartile range) follow-up of 24.8 (18.2-27.0) years, 278 incident HF events (annual 
rate 5.84/1,000 person-years at risk; 95% CI: 5.20 to 6.57) were recorded. In analyses adjusted for several 
established risk factors (age, BMI, SBP, prevalent coronary heart disease, smoking status, history of 
diabetes mellitus, use of antihypertensive agents and lipid-lowering drugs, and alcohol consumption), 
there was an inverse and continuous association between serum magnesium and incident HF, which was 
potentially consistent with either a curvilinear or approximately linear shape. However, statistical tests 
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suggested a better fit with a curvilinear shape (P for linearity > 0.05) (Figure 2 and Supplementary 
Material). The age-adjusted HR per 1 SD increase in serum magnesium levels was 0.86 (95% CI: 0.76 to 
0.97; P = 0.015), which remained consistent on further adjustment for several established and emerging 
risk factors 0.87 (95% CI: 0.76 to 0.98; P = 0.028). The results persisted after further adjusting for 
incident coronary events as shown in Table 2. Analyses with AF as a competing risk event yielded similar 
results 0.79 (95% CI: 0.62 to 99; P = 0.048) per 1 SD increase in serum magnesium levels. There was 
evidence of effect modification by history of diabetes (P for interaction=0.023), and history of CHD (P for 
interaction = 0.013). Significant inverse associations were observed in individuals with a history of 
diabetes and individuals with no history of CHD compared to non-significant associations in individuals 
with no history of diabetes and those with a history of CHD respectively (Figure 3). There were no HF 
events recorded during the first five years of follow-up, therefore results for analyses that excluded the 
first five years of follow-up were unchanged and therefore not shown. 
 
A HF risk prediction model containing established risk factors yielded a C-index of 0.7533 (95% CI: 
0.7214 to 0.7852). After addition of information on serum magnesium in the model, the C-index was 
0.7558 (0.7238 to 7878), a marginal increase of 0.0025 (-0.0035 to 0.0086; P=0.414), indicating that 
serum magnesium does not importantly improve prediction of HF risk beyond established risk factors. The 
NRI was 22.7% (-20.2 to 65.6%, P=0.299). 
 
Comment 
Summary of findings 
In this population-based prospective study of middle-aged Finnish men without HF at baseline, our results 
show a decreased risk for incident HF with increasing serum magnesium levels; however, further work is 
needed to ascertain whether a curvilinear or linear shape better describes the relationship. This association 
persisted after controlling for baseline characteristics, predictors of incident HF, metabolic and renal 
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markers, and other related micronutrients. Our data adds to the growing literature on the role of serum 
magnesium in modulating cardiovascular risk and extend the results of the elegant study by the 
Atherosclerosis Risk in Communities (ARIC) Study Investigators. Their results demonstrated that serum 
magnesium concentrations were associated with risk for HF after controlling for clinical characteristics, 
medical history, lipids, and renal function in a North American population, with the association remaining 
consistent across sex and race.(13) Taken together, these findings signal to the strength of the association 
between serum magnesium and incident HF. Our results also remained similar across several clinically 
relevant subgroups, except for evidence of effect modification by history of diabetes and prevalent CHD. 
Given the low event rate in some of the subgroups and the multiple statistical tests for interaction 
conducted, these subgroup results will require replication in further studies. Despite the high incidence of 
AF in our study cohort which might have hindered our event of interest, the association between serum 
magnesium and HF was similar when AF was adjusted for as a competing risk event. Finally, our analyses 
indicate that addition of information on serum magnesium measurements to conventional HF risk factors 
did not incrementally improve HF risk prediction.  
 
Possible explanations for findings 
A number of studies have demonstrated serum magnesium levels to be associated with several 
cardiovascular outcomes. Proposed mechanistic pathways linking low serum levels of magnesium to 
increased CVD risk include impaired glucose homeostasis and insulin resistance, high blood pressure, 
endothelial dysfunction, chronic inflammatory processes, diabetes, and impaired vascular tone and 
peripheral blood flow.(29, 30) Magnesium depletion also causes electrocardiogram abnormalities (eg, 
prolonged QTc interval) which increases the risk of cardiac arrhythmias.(30) Given that several CVD 
outcomes are closely related to the development of HF,(31-33) these same pathways may also play a role 
in the etiology between serum magnesium levels and HF. The broadly continuous and independent 
association of serum magnesium with HF may suggest a causal relationship, but this will need to be 
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demonstrated in a randomized controlled trial. A number of randomized controlled trials have shown that 
magnesium supplementation improves cardiovascular function in patients with heart failure; however, 
these do not prove causality. Establishing causality will require rigorous randomized controlled trials of 
magnesium supplementation with the appropriate endpoints. In the absence of clinical trials however, 
Mendelian randomisation (MR) studies of genetic variants specifically related to magnesium levels may 
also provide another route to assess causality.(34) Common genetic variants in the TRPM6 gene and 
ATP2B1 gene are associated with altered magnesium levels and risk for hypomagnesemia.(35) Further 
studies are needed to determine whether variants within these loci might be valid instrumental variables 
for MR studies of serum magnesium and HF.  
 
Implications of findings 
Collectively, these findings may have implications for clinical practice. Our findings further highlight the 
long-term association between baseline serum magnesium levels and risk of HF and suggest that 
magnesium might modify HF risk. Serum magnesium remains a promising though unproven strategy for 
HF risk prevention.  Animal experiments have shown that inadequate intake of magnesium is associated 
with increased atherosclerotic plaque.(36) Evidence from experimental and animal models also shows that 
magnesium therapy is beneficial in the treatment of cardiac arrhythmias.(37, 38) Observational evidence 
consistently shows that increased dietary intake of magnesium is inversely associated with several 
cardiovascular outcomes.(39-43) Urinary excretion of magnesium, which is also an indicator of dietary 
magnesium intake, has also been shown to be inversely and independently associated with CVD.(44) A 
number of clinical studies have also shown a beneficial effect of magnesium infusion on the incidence of 
cardiovascular outcomes.(45) Given that serum magnesium concentration depends on magnesium intake 
from food and water, the overall evidence supports the possibility that increasing the intake of dietary 
magnesium resulting in increased serum magnesium concentrations, might protect from the development 
of CVD outcomes including HF and also form the basis of treatment strategies. Well-designed 
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intervention trials are warranted to investigate the potential therapeutic implications of serum magnesium 
in HF prevention. Assessing serum magnesium concentration is a simple, practicable, and inexpensive test 
and its potential usefulness in HF risk prediction deserves further investigation. Formal risk assessment 
analyses involving larger-scale individual participant data are warranted to assess the usefulness of serum 
magnesium in HF risk prediction. 
 
Strengths and limitations 
The strengths include a large population-based sample that was selected to be a nationally representative, 
involved a high response rate, and there were no losses during follow-up. We had reliable definitions of 
HF outcomes which were based on ICD-10 diagnoses and information on outcomes were from established 
and reliable databases. Assay methods for serum magnesium measurements employed atomic absorption 
spectrometry which has a high level of accuracy. The mean follow-up of over 20 years was sufficiently 
long to ascertain the risk for HF. We adjusted for a comprehensive panel of lifestyle and biochemical 
markers to allow adequate adjustment for potential confounding, enabling reliable assessments of the 
associations. The limitations of the present study also deserve mention. Serum magnesium levels does not 
necessarily reflect total body magnesium content,(1) however, it is the best estimate of magnesium status 
as it correlates with ionized and intracellular magnesium.(46) We were unable to correct for within-person 
variability in serum magnesium levels as we had no data on repeat measurements. Due to the distribution 
of magnesium concentrations in the KIHD, we were unable to assess the associations at extremely low 
levels of magnesium and by clinical categories of magnesium levels. We were unable to assess the 
differential impact of serum magnesium on risk of specific forms of HF (eg. systolic versus diastolic HF 
and HF with preserved versus reduced ejection fractions), because of the absence of such data. Though we 
adjusted for several confounders, there was a possibility of residual confounding due to other unmeasured 
confounders (such as proton pump inhibitors and other medications that affect serum magnesium 
levels(47) and are associated with risk of CVD(48)), which could in part explain the association between 
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serum magnesium and HF. The study included only male Caucasians and cannot necessarily be 
extrapolated to women and other ethnicities. 
 
Conclusion 
In this middle-aged population of Finnish men, serum magnesium was found to be continuously, inversely 
and independently associated with future risk of HF. Further research is needed to assess any potential 
relevance of serum magnesium in HF prevention. 
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Figure 1. Frequency distribution of magnesium concentrations in the study sample 
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Figure 2. Hazard ratios for heart failure, by quartiles of serum magnesium levels 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, prevalent coronary 
heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents and lipid-
lowering drugs), and alcohol consumption; the mean magnesium level (mg/dl) was 1.79 for the lowest 
quartile; 1.94 for the second quartile; 2.03 for the third quartile; and 2.18 for the top quartile 
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Figure 3. Hazard ratios for serum magnesium levels and heart failure risk by several participant level 
characteristics  
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Hazard ratios were adjusted age, body mass index, systolic blood pressure, prevalent coronary heart 
disease, smoking status, history of diabetes, use of medications (antihypertensive agents and lipid-
lowering drugs), and alcohol consumption; CHD, coronary heart disease; CI, confidence interval; GFR, 
glomerular filtration rate; HF, heart failure; HR, hazard ratio; SD, standard deviation; *, P-value for 
interaction; Cut-offs used for age, body mass index, systolic blood pressure, total cholesterol, estimated 
GFR, and follow-up time are median values. 
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Table 1. Baseline characteristics and cross-sectional correlates of serum magnesium 
  
Mean (SD), median 
(IQR), or % 
Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in 
magnesium levels per 1 SD higher or 
compared to reference category of 
correlate‡ 
Magnesium (mg/dl) 1.98 (0.16) - - 
    
Questionnaire/Prevalent conditions    
Age at survey (years) 53.0 (5.0) 0.06 (0.02, 0.10)* 1% (0, 2)* 
Alcohol consumption (g/week) 76.3 (139.2) -0.09 (-0.13, -0.04)*** -1% (-2, -1)*** 
History of diabetes    
    No 96.4 - Ref 
    Yes 3.6 - -7% (-10, -3)** 
Smoking status    
    Other 68.1 - Ref 
    Current 31.9 - -1% (-2, 0) 
History of hypertension    
    No 72.0 - Ref 
    Yes 28.0 - -2% (-3, -0)* 
History of CHD    
    No 77.9 - Ref 
    Yes 22.1 - 0% (-1, 2) 
Use of anti-hypertensives    
    No 81.3 - Ref 
    Yes 18.7 - -1% (-3, 0) 
Medication for dyslipidemia    
    No 99.4 - Ref 
    Yes 0.6 - -6% (-14, 2) 
    
Physical measurements    
BMI (kg/m2) 26.8 (3.5) -0.03 (-0.07, 0.01) -0% (-1, 0) 
SBP (mmHg) 133.7 (16.7) -0.04 (-0.09, -0.00) -1% (-1, -0)* 
DBP (mmHg) 88.6 (10.4) -0.03 (-0.07, 0.01) -0% (-1, 0) 
Physical activity (kj/day) 1,512.8 (1,368.1) 0.00 (-0.04, 0.04) 0% (-1, 1) 
    
Lipid markers    
Total cholesterol (mmol/l) 5.90 (1.10) 0.08 (0.04, 0.12)*** 1% (1, 2)** 
HDL-C (mmol/l) 1.31 (0.30) -0.03 (-0.07, 0.01) -0% (-1, 0) 
Triglycerides (mmol/l) 1.08 (0.79-1.52) -0.00 (-0.04, 0.04) -0% (-1, 1) 
    
Metabolic, biochemical, and renal markers    
Fasting plasma glucose (mmol/l) 5.33 (1.18) -0.14 (-0.19, -0.10)*** -2% (-3, -2)*** 
Serum creatinine (µmol/1) 89.5 (21.0) 0.14 (0.10, 0.18)*** 2% (2, 3)*** 
Serum potassium (mmol/l) 3.92 (0.30) -0.01 (-0.05, 0.04) -0% (-1, 1) 
Serum zinc (mg/l) 0.94 (0.12) 0.11 (0.07, 0.15)*** 2% (1, 2)*** 
Estimated GFR (ml/min/1.73 m2) 87.3 (17.3) -0.14 (-0.18, -0.10)*** -2% (-3, -2)*** 
 
BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL-C, high-density 
lipoprotein cholesterol; IQR, interquartile range; SD, standard deviation; SBP, systolic blood pressure; †Pearson correlation coefficients between 
serum magnesium and the row variables;. ‡Percentage change in magnesium levels per 1-SD increase in the row variable (or for categorical 
variables, the percentage difference in mean magnesium levels for the category versus the reference) adjusted for age; asterisks indicate the level 
of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001 
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Table 2. Association of serum magnesium levels with heart failure 
 
Magnesium, mg/dl Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 278 / 2,181 0.86 (0.76-0.97) 0.015 0.87 (0.77-0.98) 0.027 0.87 (0.76-0.98) 0.028 0.86 (0.76-0.98) 0.019 
 
 
SD, standard deviation 
Model 1: Adjusted for age 
Model 2: Model 1 plus body mass index, systolic blood pressure, prevalent coronary heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents 
and lipid-lowering drugs), and alcohol consumption 
Model 3: Model 2 plus triglycerides, total cholesterol, high-density lipoprotein cholesterol, estimated glomerular filtration rate, socio-economic status, physical activity, serum 
potassium, and serum zinc 
Model 4: Model 3 plus incident coronary heart disease as a time-dependent covariate 
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Supplementary Material: Hazard ratios for heart failure using multivariate-adjusted fractional polynomials 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, prevalent coronary 
heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents and lipid-
lowering drugs), and alcohol consumption 
 
 
 
 
 
